Orexigen Therapeutics (OREX) Tops Q3 EPS by 78c, Miss on Revenues

Orexigen Therapeutics (NASDAQ: OREX) reported Q3 EPS of ($1.35), $0.78 better than the analyst estimate of ($2.13). Revenue for the quarter came in at $18.9 million versus the consensus estimate of $24.2 million.

For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.

You May Also Be Interested In

• SYNNEX Corp. (SNX) Tops Q3 EPS by $1.04, Beats on Revenue; Offers Q4 Guidance
• Uxin Limited (UXIN) Reports Q3 EPS of $0.00
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance